Shares of STRATA Skin Sciences, Inc. (NASDAQ: SSKN) experienced a notable increase on the stock market following promising peer-reviewed clinical trial results. After completing the previous session at $3.56, SSKN stock gained 13.02%; however, as of the most recent check made today, it was up 3.60% to $3.69.
Revolutionary Research
In the July 11, 2024, issue of the Journal of Cosmetic and Laser Therapy, STRATA (SSKN) just announced the publication of a clinical trial titled, “Advancing Precision Acne Therapy Using a Photopneumatic Device.” The research showed that following one to three treatments, the TheraClearX Acne Therapy System significantly improved skin texture and pore size in addition to reducing acne lesions and the redness that goes along with them.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
These benefits were achieved with minimal adverse effects, supporting the device’s use as both a monotherapy and an adjunct treatment. The system’s customizable features, such as adjustable pulse structure, pulse duration, vacuum pressure, and energy intensity, enabled tailored treatments suited to various skin types and acne conditions.
Detailed Evaluation and Findings
The purpose of the study was to evaluate the observable changes in skin texture and acne lesions in individuals with mild to moderate acne following a course of individualized photopneumatic treatment applications. Seven female participants with inflammatory, comedonal, and pustular lesions underwent up to six treatments, spaced one to two weeks apart, with each session lasting 15-20 minutes using personalized energy settings.
STRATA’s TheraClearX is an FDA-cleared, noninvasive, in-office treatment designed for mild to moderate acne, including comedonal, pustular, and inflammatory acne vulgaris. The device efficiently treats acne by combining pulsed broadband light with a mild vacuum.
The vacuum draws dermal structures toward the skin surface, extracting follicle contents, while the broadband light activates porphyrins to eradicate Cutibacterium acnes and reduce sebum production. The vacuum is released upon completion of the process. The treatment is delivered through a liquid-cooled handheld device, ensuring patient comfort and requiring no pre-medication or anesthesia, with no downtime post-treatment.
Consistent and Promising Results
The results of this study align with the known clinical efficacy of the TheraClearX device and other published research on the benefits of photopneumatic therapy for mild to moderate acne. Acne affects millions annually in the U.S. alone and often proves challenging to treat with topical or oral medications alone. Photopneumatic therapy is emerging as a viable treatment option, and it is encouraging to see consistent positive results across a growing number of investigator-initiated studies.
